Celgene(NASDAQ: CELG) recently reported that its multiple sclerosis drug, ozanimod, successfully met its endpoints in reducing multiple sclerosis (MS) relapses, and assuming a second trial pans out ...
A new and highly anticipated study byCelgene Corp. (NASDAQ: CELG) shows that its promising multiple sclerosis drug could soon reshape the $19 billion multiple sclerosis market. On Friday, management ...
Amgen said Monday that it will buy the psoriasis pill Otezla from Celgene, which is selling the medicine to remove an antitrust obstacle from its planned merger with Bristol-Myers Squibb. The purchase ...
Celgene will sell its psoriasis drug Otezla for $13.4 billion in cash to Amgen The sale takes Celgene a step closer to a $74-billion takeover by Bristol-Myers Squibb. The company in June offered to ...
REVLIMID® and rituximab (R2) has the potential to become a chemotherapy-free combination treatment option for patients with follicular lymphoma who have relapsed or did not respond to previous ...
(Reuters) - Celgene Corp said on Tuesday it would buy Receptos Inc for $7.2 billion in a move that will give the U.S. biotechnology company a potential multibillion-dollar drug in late stage ...
Sol J. Barer will be stepping down in June as the chief executive officer of Summit-based drug maker Celgene, the company announced last week. Barer will be replaced by the current president and chief ...
(Reuters) - Celgene Corp's treatment for anemia in patients with beta thalassemia, a rare blood disorder, would be priced at $3,441 for a 25-milligram vial of the drug, partner Acceleron Pharma Inc ...
Amgen said Monday that it will buy the psoriasis pill Otezla from Celgene, which is selling the medicine to remove an antitrust obstacle from its planned merger with Bristol-Myers Squibb. The purchase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results